Exercise set

Implantable Device Biocompatibility, Sterility, and Release Evidence Exercises

Worked implantable-device exercises for leachables, sterility, packaging, insulation, sampling, CT inspection and release evidence.

Branch: Biomedical Engineering
Content: Exercise set
Updated: Jul 03, 2026
Revision: v1.0.0 · reviewed

These exercises focus on implantable-device release evidence: biocompatibility screens, leachable exposure, extractables, drug-release claims, sterile barrier moisture ingress, sterilization, packaging integrity, insulation leakage, sampling coverage, field failure rate, CT inspection and final release gates.

Biomaterial mechanics, corrosion, wear and coating adhesion are handled in the companion specialist exercise set. This page stays on the finished implantable device and the evidence package needed before release.

Release Evidence Notes

Implantable-device release evidence should identify the finished device configuration, material lot, body-contact category, contact duration, sterilization method, packaging state, shelf-life claim, manufacturing process, inspection method, measurement uncertainty and residual-risk decision. Evidence that applies only to raw material, coupon geometry or a nonsterile prototype cannot be used without a boundary statement.

Engineering Boundary Notes

These examples are simplified engineering screens, not regulatory advice. Real implantable-device release requires biological evaluation, sterilization validation, packaging validation, process validation, design verification, risk management, clinical or simulated-use justification where applicable and controlled change review.

Common Release Mistakes

using extract data without converting to per-device exposure;
accepting a sterile process while packaging or aging evidence is weak;
treating insulation resistance as only an electronics metric;
reporting validation sample counts without configuration coverage;
accepting CT inspection without comparing detection limit to critical flaw size;
averaging release gates when one severe residual risk remains open.

Scenario Map

Scenario	Exercises	Main calculation	Release decision
Chemical and biological evidence	1, 2, 3, 11	Leachable exposure, extract margin, dose window and evidence coverage	Support or narrow the biological/contact claim.
Sterility and packaging	4, 5, 6, 7, 8, 17	Moisture ingress, desiccant capacity, log reduction, seal margin, package sample and aging evidence	Release, repackage or extend validation.
Electrical and inspection evidence	9, 15	Leakage current and CT action flaw	Accept, reject or improve test sensitivity.
Lifecycle release	10, 12, 13, 14, 16, 18	Sampling, RPN, field rate, complaints, traceability and integrated release	Hold release when evidence coverage or residual risk fails.

Validation Package Checklist

finished-device configuration and body-contact boundary;
biological, chemical, electrical, packaging and sterilization evidence;
lot, supplier, process, cleaning and aging state;
sampling plan and configuration coverage;
inspection sensitivity compared with action criteria;
release action for unresolved residual risk or missing evidence.

Exercise 1: Leachable Daily Exposure

An extraction study measures concentration $C=36\ \mu\text{g/L}$ in $0.50\ \text{L}$ of extract representing $3$ devices. Assume $80\%$ of the mass could be released on day one. Estimate daily exposure per device.

Solution

m_{total}=36(0.50)=18\ \mu\text{g}

m_{device}=\dfrac{18}{3}=6\ \mu\text{g}

E_1=0.80(6)=4.8\ \mu\text{g/day}

Engineering Comment

The calculation converts extract concentration into device exposure. The biological interpretation still needs toxicological context and uncertainty.

Plausibility Check

The total mass is eighteen micrograms across three devices, so six micrograms per device is reasonable.

Exercise 2: Guarded Extractables Margin

A first-day exposure limit is $5.0\ \mu\text{g/day}$ . The estimate is $4.2\ \mu\text{g/day}$ with uncertainty $0.6\ \mu\text{g/day}$ . Does it pass with guard band?

Solution

E_g=4.2+0.6=4.8\ \mu\text{g/day}

Since:

4.8<5.0

the guarded screen passes.

Engineering Comment

The margin is narrow. A change in material lot, cleaning, sterilization or packaging could remove it.

Plausibility Check

Adding the uncertainty moves the estimate close to the limit but not above it.

Exercise 3: Drug-Release Dose Window

A coating releases $2.4\ \mu\text{g/h}$ for $24\ \text{h}$ . Only $70\%$ is expected to reach the target region. The target daily window is $35$ to $50\ \mu\text{g}$ . Does it pass?

Solution

D=2.4(24)(0.70)=40.3\ \mu\text{g/day}

The result is within the window.

Engineering Comment

The screen supports the release claim only if burst release, depletion, shelf life, sterilization and local transport are controlled.

Plausibility Check

The total coating release is $57.6\ \mu\text{g}$ , and seventy percent is about forty micrograms.

Exercise 4: Sterile-Barrier Moisture Ingress

A pouch has area $0.018\ \text{m}^2$ , WVTR $0.12\ \text{g/(m}^2\text{ day)}$ and shelf-life claim $730\ \text{days}$ . Estimate moisture ingress.

Solution

m=0.018(0.12)(730)=1.58\ \text{g}

Engineering Comment

Moisture ingress can change coating hydration, corrosion, polymer strength, insulation resistance or drug release even when sterility is preserved.

Plausibility Check

The daily ingress is only $0.00216\ \text{g/day}$ , but two years accumulates grams.

Exercise 5: Desiccant Capacity Margin

The desiccant capacity is $2.4\ \text{g}$ and predicted moisture ingress is $1.58\ \text{g}$ . Compute margin.

Solution

M=2.4-1.58=0.82\ \text{g}

Engineering Comment

Positive capacity margin should be supported by placement, package seal evidence, aging and transport exposure.

Plausibility Check

The desiccant capacity is roughly one gram above the predicted ingress.

Exercise 6: Sterilization Log Reduction

A sterilization process starts with bioburden estimate $10^4$ organisms and provides $8$ log reduction. Estimate residual organism count.

Solution

N=10^4(10^{-8})=10^{-4}

Engineering Comment

This simplified screen shows large reduction, but real sterility assurance depends on process validation, load configuration, packaging and monitoring.

Plausibility Check

An eight-log reduction applied to four logs leaves negative four logs, or $10^{-4}$ .

Exercise 7: Seal Strength Margin

A sterile barrier seal has measured strength $1.45\ \text{N/mm}$ . The requirement is $1.20\ \text{N/mm}$ with uncertainty $0.08\ \text{N/mm}$ . Compute guarded margin.

Solution

M_g=1.45-1.20-0.08=0.17\ \text{N/mm}

Engineering Comment

Seal strength should be paired with leak testing, aging, transport simulation and point-of-use opening evidence.

Plausibility Check

The nominal margin is $0.25$ , and the uncertainty guard leaves $0.17$ .

Exercise 8: Package Integrity Sample Completion

A packaging validation plan requires $90$ sterile-barrier samples across aging and transport conditions. Testing completes $84$ . Compute completion.

Solution

C=\dfrac{84}{90}=93.3\%

Engineering Comment

Completion percentage is not enough if the missing samples represent the worst-case aging or transport condition.

Plausibility Check

Six samples are missing from ninety, so completion is slightly above ninety percent.

Exercise 9: Insulation Resistance and Leakage Current

An active implant feedthrough has insulation resistance $R=80\ \text{M}\Omega$ under test voltage $V=10\ \text{V}$ . Compute leakage current.

Solution

I=\dfrac{V}{R}=\dfrac{10}{80\times10^6}=1.25\times10^{-7}\ \text{A}=0.125\ \mu\text{A}

Engineering Comment

Leakage current is a device-level safety and materials issue because moisture, cleaning residue, insulation defects and aging can change it.

Plausibility Check

Ten volts across tens of megaohms gives a fraction of a microampere.

Exercise 10: Validation Sampling Completion

A validation matrix has $42$ required material-process-sterilization combinations. Evidence exists for $38$ . Compute coverage.

Solution

C=\dfrac{38}{42}=90.5\%

Engineering Comment

Coverage may still fail if the four missing combinations are worst-case or newly changed configurations.

Plausibility Check

Four missing combinations out of forty-two leaves a little over ninety percent.

Exercise 11: Biocompatibility Evidence Matrix

A biological evaluation plan lists $14$ required evidence lines. Twelve are complete, one is justified by rationale and one is open. Compute closed evidence fraction if complete and justified lines count as closed.

Solution

C=\dfrac{12+1}{14}=92.9\%

Engineering Comment

The open line may be a blocker if it relates to a severe endpoint or changed patient-contact material.

Plausibility Check

Thirteen of fourteen lines are closed, so the fraction should be near ninety-three percent.

Exercise 12: Residual RPN for Coating Delamination

An implant coating delamination mode has severity $8$ , occurrence $3$ and detection $4$ after controls. Compute residual RPN.

Solution

RPN=8(3)(4)=96

Engineering Comment

If severity remains high, the release decision should check whether residual risk is acceptable, not only whether RPN decreased.

Plausibility Check

The product of three small integers with severity eight is just under one hundred.

Exercise 13: Field Failure Rate Screen

Field monitoring finds $5$ confirmed implant-related material complaints over $22000$ implant-months. Compute complaint rate per $1000$ implant-months.

Solution

\lambda=\dfrac{5}{22000}(1000)=0.227\ \text{per }1000\text{ implant-months}

Engineering Comment

Complaint rate must be interpreted with reporting sensitivity, exposure definition, severity, lot clustering and failure-mode classification.

Plausibility Check

Five events in twenty-two thousand months is a low rate, well below one per thousand months.

Exercise 14: Complaint Trend Trigger

A monitoring rule triggers review if current-quarter complaints exceed baseline by more than $40\%$ . Baseline is $10$ complaints per quarter and current count is $15$ . Does it trigger?

Solution

R=\dfrac{15-10}{10}=50\%

Since $50\%>40\%$ , the trigger is exceeded.

Engineering Comment

Trend triggers should lead to lot, process, complaint coding and clinical-use review before the signal is dismissed.

Plausibility Check

An increase from ten to fifteen is half of the baseline.

Exercise 15: CT Inspection Action Flaw

Critical flaw size is $2.7\ \text{mm}$ and the release rule sets action flaw size at one third of critical size. Qualified CT detection is $0.75\ \text{mm}$ . Does detection support the action limit?

Solution

a_{action}=\dfrac{2.7}{3}=0.90\ \text{mm}

Since:

0.75<0.90

the CT method can detect flaws smaller than the action limit.

Engineering Comment

Detection support still needs geometry, artefact, orientation and probability-of-detection evidence.

Plausibility Check

One third of $2.7$ is $0.9$ , and $0.75$ is below it.

Exercise 16: Lot Traceability Coverage

A release lot contains $480$ devices. Full traceability records are complete for $474$ devices. Compute traceability coverage.

Solution

C=\dfrac{474}{480}=98.75\%

Engineering Comment

For implantable devices, missing traceability can be a release blocker even when percentage coverage looks high.

Plausibility Check

Only six records are missing, so coverage is close to one hundred percent.

Exercise 17: Accelerated Aging Evidence

A package aging plan uses acceleration factor $AF=5.0$ for a $2$ year shelf-life claim. How much real-time aging is represented by $160$ days of accelerated aging?

Solution

t_{eq}=160(5.0)=800\ \text{days}=2.19\ \text{years}

Engineering Comment

The time equivalence passes the nominal duration, but real-time aging and worst-case storage evidence may still be required.

Plausibility Check

Five times one hundred sixty days is eight hundred days, slightly above two years.

Exercise 18: Implantable Device Release Gate

A release requires guarded leachable exposure below limit, package moisture margin positive, leakage current below $0.50\ \mu\text{A}$ , CT detection below action flaw and no open severe biocompatibility evidence line. Results are pass, pass, $0.125\ \mu\text{A}$ , pass and one open severe line. Does it release?

Solution

The severe open evidence line blocks release:

\text{open severe line}=1>0

The integrated release fails.

Engineering Comment

Implantable-device release should not average evidence gates. A severe unresolved biological or material concern overrides favorable numerical screens.

Plausibility Check

All numerical screens pass, but the stated release rule includes a zero-open-severe-line condition.

REF